Stada Arzneimittel AG is weighing offers as a bidding war for one of the last remaining generic-drug businesses of its size in Germany and Russia begins to unfold. The company said Thursday it received interest from a third firm that made a non-binding offer of 58 euros a share, or about 3.61 billion euros .